The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

The agreement, signed Monday between CMS and DHS, has not been announced publicly, AP reports. Other Trump administration ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

A study, which polled more than 1,200 people, found that participants were less willing to book appointments when any type of AI use was indicated. More industry news is on the fund to bolster rural ...